← Back to Search

Nucleoside Analog

MT1621 for Thymidine Kinase Deficiency

Phase 3
Waitlist Available
Research Sponsored by Zogenix MDS, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

Study Summary

This study is evaluating whether a drug called MT1621 can improve the health of children with a rare genetic disease.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of subjects acquiring a Motor Milestone
Secondary outcome measures
Survival
Time to Acquisition of a Motor Milestone

Trial Design

1Treatment groups
Experimental Treatment
Group I: Single ArmExperimental Treatment1 Intervention
Male and female Participants <18 years

Find a Location

Who is running the clinical trial?

Zogenix MDS, Inc.Lead Sponsor
3 Previous Clinical Trials
146 Total Patients Enrolled
Modis Therapeutics, Inc.Lead Sponsor
3 Previous Clinical Trials
146 Total Patients Enrolled
Zogenix, Inc.Industry Sponsor
24 Previous Clinical Trials
2,573 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~0 spots leftby Mar 2025